COMMUNIQUÉS West-GlobeNewswire

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
29/10/2025
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKs [...]
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
29/10/2025
Data from the dose optimization trial expected soon ProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the [...]
Betterguards Launches The BetterGuard Lite, a Powerful New Ankle Protection System with Breakthrough Design
29/10/2025
The BetterGuard Lite features an impossibly thin, lightweight design at an affordable price for athletes worldwide NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Betterguards , a sports technology innovator, today [...]
FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
29/10/2025
First orphan designation ever granted to a condensate-modulating therapeutic Builds on recent IND opening for DPTX3186, a first-in-class oral condensate modulator targeting the Wnt/ β -catenin pathway Provides key [...]
OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
29/10/2025
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 [...]
MEDIROM to Launch New Treasury Strategy Utilizing Cryptocurrency
29/10/2025
Aimed at incentivize large-scale vital data collection TOKYO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc., (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on the [...]
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
29/10/2025
NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit 1 Data showed consistent improvements across secondary outcome measures, and a favorable safety [...]
Plum Tree Launches New Chronic Illness Therapy Program
29/10/2025
ST. CHARLES, Ill., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Plum Tree Psychology, Ltd., a leading child and family mental health practice in the Fox Valley, today announced the launch of Hoot & Holler, a new Chronic [...]
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
29/10/2025
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results show ~60% of VYVGART [...]
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
29/10/2025
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living [...]
Virginia Cannabis Dispensary Cannisco Unveils New Brand Identity as East Coast Collective Transitions
29/10/2025
Shenandoah Valley-Based Hemp Company Rebrands to Reflect Commitment to Quality, Integrity, and Seed-to-Sale Excellence Shenandoah Valley, Virginia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Cannisco , formerly East Coast [...]
Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025
29/10/2025
- First-in-human data validating direct targeting of NETs as a novel therapeutic approach in autoimmunity and inflammatory diseases - DNASE1L3 analogue therapy degrades NETs and results in rapid, multi-organ clinical [...]
Vireo Growth Inc. and Verano Holdings Corp. Announce Resolution of Litigation Matters
29/10/2025
CHICAGO and MINNEAPOLIS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Verano Holdings Corp. (“Verano”, Vireo and Verano, each a “Company”) (Cboe CA: VRNO) (OTCQX: VRNOF) [...]
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
29/10/2025
BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business [...]
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
29/10/2025
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
29/10/2025
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) ‘time saved’ with oral blarcamesine compared to ADNI Restoring impaired [...]
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
29/10/2025
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Hyperion DeFi Announces Strategic Partnership with Felix to Launch HIP-3 Powered Perpetual Futures Market
29/10/2025
New Hyperliquid Product Compounds Yield on 500,000 HYPE Staked by the Company LAGUNA HILLS, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S [...]
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
29/10/2025
Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- [...]

Pages